Share Twitter LinkedIn Facebook Email Pascal Besman, Chief Operating Officer of PharmaMar, talks about Lurbinectedin More Pronounced in Overall Survival | OS Endpoint is Preferable from Regulatory POV at Annual Meeting 2018
HARPOON THERAPEUTICS: New data on HPN328 T cell engager at ESMO 2023 Small Cell Lung Cancer 2 Mins Read
Emerging Treatment for SCLC – Leading Developments & Current Questions in Lung Cancer Small Cell Lung Cancer 1 Min Read
CAR T-Cell Therapy: Promising Results Against Small Cell Lung Cancer Renier Brentjens MD Small Cell Lung Cancer 1 Min Read